STOK Stock — Stoke Therapeutics Inc.: Cash, EV, Pipeline

Share price

$28.43

Market cap

$1,834.5M

Cash

$292.8M

Enterprise value

$1,541.7M

Balance sheet

Cash	$292.8M
Debt	$0.0M
Net cash	$292.8M
Enterprise value	$1,541.7M
Basic shares	62.4M shares
Fully diluted shares	83.2M shares
Fully diluted market cap	$2,366.0M
Cash per share	$4.69

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading STOK daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24	zorevunersen	Phase 3	Dravet Syndrome	Q3 2027
May 12 - Jun 23	zorevunersen (STK-001)	Phase 2	Dravet Syndrome	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

zorevunersen

Phase 3 · Active Modality: ASO (TANGO protein-upregulation)

Aliases STK-001

Target SCN1A (Nav1.1)

Partnerships Biogen: exclusive license to develop and commercialize outside the US, Canada and Mexico; joint development with Company leading globally (70/30 cost share)

Indications

Dravet syndrome (Phase 3)

Catalysts

— Q1 2027
— Q3 2027 / H2 2027
— early 2028

Status note Lead candidate. Global pivotal Phase 3 EMPEROR study enrolled 162 patients (completed June 2026); Phase 1/2a and OLE studies completed. Breakthrough Therapy Designation (Dec 2024).

STK-002

Phase 1 · Active Modality: ASO (TANGO protein-upregulation)

Target OPA1

Indications

Autosomal dominant optic atrophy (ADOA) (Phase 1)

Catalysts

— H1 2027

Status note Phase 1 OSPREY dose-escalation study ongoing; first patient dosed February 2026; eight sites active across UK, Germany, Austria, Italy and Denmark.

Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	zorevunersen
Lead indication	Dravet Syndrome
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06872125	Phase 3	Recruiting	Sponsor	STOK	—	Dravet Syndrome	Q3 2027
NCT04740476	Phase 2	Active, not recruiting	Sponsor	STOK	—	Dravet Syndrome	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Stoke Therapeutics, Inc on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	5,623,525	no change	1.57%	2026-08-14
Baker Bros. Advisors	3,336,697	no change	0.55%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

STOK — Stoke Therapeutics Inc.